NORTHSIDE HOSPITAL - GWINNETT
The Sunshine Act requires manufacturers to report payments to teaching hospitals as institutions, separately from payments to individual physicians. These figures are money reported to the hospital itself — most of it research funding and grants, not compensation to any named doctor.
- Total reported
- $17M
- Transactions
- 1,802
- Companies
- 40
- Average per transaction
- $9,427
Who reported the payments
| Pfizer | $1,868,227 |
| Sanofi US Services Inc. | $1,495,562 |
| Merck | $1,372,602 |
| Seagen Inc. | $1,355,641 |
| Deciphera Pharmaceuticals Inc. | $1,227,699 |
| E.r. Squibb & Sons, L.L.C. | $1,101,745 |
| Bristol Myers Squibb | $1,060,103 |
| AstraZeneca | $912,610 |
| Abbott | $767,722 |
| Eli Lilly | $580,876 |
| National Marrow Donor Program | $457,457 |
| CSL Behring | $400,927 |
| Gilead | $295,281 |
| Angiodynamics, Inc. | $271,583 |
| Astellas Pharma Global Development | $270,317 |
| Pharmacyclics LLC, An Abbvie Company | $267,326 |
| Genentech, Inc. | $256,133 |
| G1 Therapeutics, Inc. | $253,614 |
| Jazz Pharmaceuticals Inc. | $226,254 |
| Blue Earth Diagnostics | $199,209 |
| Partner Therapeutics, Inc. | $198,977 |
| Janssen Research & Development, LLC | $136,158 |
| ADC Therapeutics America, Inc. | $135,203 |
| Novartis | $127,586 |
| Amgen | $126,842 |
| Sanofi-aventis U.S. LLC | $111,372 |
| Boston Scientific | $95,377 |
| AbbVie | $89,415 |
| Trillium Therapeutics USA, LLC | $80,818 |
| Exelixis Inc. | $74,106 |
| Biosense Webster, Inc. | $73,535 |
| Morphosys AG | $70,075 |
| Takeda Pharmaceuticals U.S.A., Inc. | $61,214 |
| Lunit Americas, Inc. | $59,733 |
| F. Hoffmann-la Roche AG | $58,995 |
| Modernatx, Inc. | $57,759 |
| Stryker | $55,166 |
| Radius Health, Inc. | $52,726 |
| Portola Pharmaceuticals, LLC | $50,305 |
| Shockwave Medical, Inc | $43,969 |